Keystone Symposia

Fairmont Chateau Whistler Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2015


Here are the related meetings in 2020:
Obesity and NAFLD: Mechanisms and Therapeutics (B3)

For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Obesity and the Metabolic Syndrome: Mitochondria and Energy Expenditure (X7)


Organizer(s) Johan Auwerx, Eleftheria Maratos-Flier and Thomas Langer
March 22—27, 2015
Fairmont Chateau Whistler • Whistler, BC Canada
Discounted Abstract Deadline: Nov 20, 2014
Abstract Deadline: Dec 18, 2014
Scholarship Deadline: Nov 20, 2014
Discounted Registration Deadline: Jan 21, 2015

Sponsored by Nestlé Institute of Health Sciences and Novo Nordisk A/S


Summary of Meeting:
A medical challenge of the 21st century is the coupling of an unprecedented increase in life expectancy with a large increase in incidence and prevalence of chronic multifactorial diseases. Classic disease examples include disorders of metabolism such as obesity and type 2 diabetes mellitus, which are often associated with co-morbidities including non-alcoholic liver disease and coronary, peripheral and central vascular disease. Collectively, the spectrum of disorders is often referred to as the metabolic syndrome. Over the past decade, it has become evident that shifts in cellular metabolism are often linked to changes in the number, morphology and function of mitochondria, and that these cellular changes underlie systemic metabolic abnormalities that characterize the many clinical features of the metabolic syndrome. This meeting will discuss novel findings that link mitochondrial function in peripheral tissues, such as liver, muscle and gut, with the systemic abnormalities of the metabolic syndrome. The potential for identifying new therapeutics that are based on modifying mitochondrial function will be reviewed. As mitochondrial function is now acknowledged to also control metabolic homeostasis on an organismal level in addition to controlling energy homeostasis at the cellular level, this meeting will create a truly interdisciplinary environment that brings together basic scientists in the fields of bioenergetics, physiology, and mitochondrial and cell biology, and clinicians with an interest in metabolic disease, to foster innovative ideas in this area.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 12 hr (am/pm) time


SUNDAY, MARCH 22

16:00—20:00
Arrival and Registration

Macdonald Foyer
18:00—20:00
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Macdonald Foyer

MONDAY, MARCH 23

07:00—08:00
Breakfast

Frontenac ABC
08:00—09:00
Keynote Address

Macdonald DEF
* Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland

Jodi Nunnari, University of California, Davis, USA
Molecular Mechanisms of Mitochondrial Behavior

08:00—09:00
Keynote Address

Macdonald ABC
* Jay D. Horton, University of Texas Southwestern Medical Center, USA

Randal J. Kaufman, Sanford-Burnham Medical Research Institute, USA
ER Stress in NAFLD and Its Progression to NASH

09:00—11:15
Mitochondrial Function and Morphology and the Metabolic Syndrome

Macdonald DEF
* Andrew G. Dillin, University of California, Berkeley, USA

Orian S. Shirihai, University of California, Los Angeles, USA
Mitochondrial Fission/Fusion and Pancreatic Function

David C. Chan, California Institute of Technology, USA
Regulation of Mitochondrial Fusion

Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland
Mitonuclear Protein Balance as a Determinant of Health- and Lifespan

09:00—11:15
Hepatic Flux in NAFLD

Macdonald ABC
* Jay D. Horton, University of Texas Southwestern Medical Center, USA

Shawn C. Burgess, University of Texas Southwestern Medical Center, USA
Obesity’s Beast of Burden

Brian N. Finck, Washington University School of Medicine, USA
New Pathways for Targeting Metabolic Disease and Hepatic Steatosis

Eric B. Taylor, University of Iowa, USA
Regulation of Hepatic Gluconeogenesis by Mitochondrial Pyruvate Carrier 1

09:40—10:00
Coffee Break

Macdonald Foyer
11:15—13:00
Poster Setup

Frontenac ABC
13:00—22:00
Poster Viewing

Frontenac ABC
11:15—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Quality Control in Mitochondria and the Metabolic Syndrome

Macdonald DEF
* Jodi Nunnari, University of California, Davis, USA

Thomas Langer, CECAD Research Center, Germany
Mitochondrial Proteolysis and Metabolic Control

Andrew G. Dillin, University of California, Berkeley, USA
Ablation of Olfactory Sensory Neurons Reprograms Peripheral Metabolism

Jonathan R. Friedman, University of California, Davis, USA
Short Talk: MICOS, Respiratory Complexes and Mitochondrial Lipids Coordinately Build a Functional Mitochondrial Inner Membrane

Benjamin D. Stein, The Salk Institute for Biological Studies, USA
Short Talk: Quantitative Proteomics Screen Using Stable Isotope Labeling in Mammals Identifies Novel AMPK Substrates in Mouse Liver

17:00—19:00
Liver Metabolism in Human Health and Disease

Macdonald ABC
* Samuel Klein, Washington University School of Medicine, USA
Metabolic Implications of NAFLD in Obesity

Hannele Yki-Järvinen, University of Helsinki, Finland
NAFLD and Hepatic Insulin Resistance in the Human Liver

Michael Roden, Universitätsklinikum Düsseldorf, Germany
Quantifying Hepatic Energetics in Health and Disease

Elizabeth K. Speliotes, University of Michigan, USA
Short Talk: Genetic Variation in FXR/RXR Pathway Genes that Play a Role in Bile Acid, Cholesterol, Lipid and Carbohydrate Metabolism Predispose to Nonalcoholic Fatty Liver Disease in Humans

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac ABC
19:30—22:00
Poster Session 1

Frontenac ABC

TUESDAY, MARCH 24

07:00—08:00
Breakfast

Frontenac ABC
07:30—08:00
Poster Setup

Frontenac ABC
08:00—17:00
Poster Viewing

Frontenac ABC
08:00—11:00
Gastrointestinal Lipid Signaling and the Metabolic Syndrome (Joint)

Macdonald ABCDEF
* Anu Suomalainen Wartiovaara, University of Helsinki, Finland

Kristina Schoonjans, École Polytechnique Fédérale de Lausanne – EPFL, Switzerland
The Bile Acid Receptor TGR5 at the Crossroads of Inflammation and Metabolism

Eleftheria Maratos-Flier, Beth Israel Deaconess Medical Center, USA
New Insights into NAFLD: Fructose, Fat and FGF21

David D. Moore, Baylor College of Medicine, USA
FXR as an Integrator of the Fed State in the Liver

Junichiro Sonoda, Regeneron Pharmaceuticals, Inc., USA
Stimulating Brown Fat with a Therapeutic Antibody

Allyson N. Hamlin, University of Cincinnati, USA
Short Talk: Hepatic LRP1 Deficiency Exacerbates Microsteatosis and Hepatocyte Cell Death via Lysosomal Insufficiency

09:20—09:40
Coffee Break

Macdonald Foyer
11:00—12:00
Lunch

Frontenac ABC
12:00—14:30
Poster Session 2

Frontenac ABC
14:30—16:30
Workshop 1: Mitochondria and Muscle

Macdonald DEF
* Reuben J. Shaw, The Salk Institute for Biological Studies, USA

Thomas Philip Agnew, University of Oxford, UK
oboe – A Novel Mouse Model of Mitochondrial Disease with Reduced Adiposity and Hypertrophic Cardiomyopathy

Weiwei Fan, The Salk Institute for Biological Studies, USA
Ppardelta-Mediated Shift in Muscle Mitochondrial Substrate Boosts Energy Expenditure and Attenuates Diet-Induced Obesity

David E. Cohen, Brigham and Women's Hospital, Harvard Medical School, USA
Thioesterase Superfamily Member 2 (Them2) Channels Fatty Acids to Glycerol-3-Phosphate Acyltransferase-1 (GPAT1): Role in Hepatic Insulin Resistance

Takashi Nakagawa, University of Toyama, Japan
NAD Synthesis Enzyme, Nmnat3 Protects against High Fat Diet- and Age-Induced Obesity in Mice

Eric S. Muise, Merck & Co., Inc., USA
Acute Treatment of Mice with Potent AMPK Activators Mimics Acute Exercise-Induced Transcriptional Effects in Skeletal Muscle

Mario Ost, German Institute of Human Nutrition, Germany
Muscle Mitohormesis Promotes Cellular Survival via Serine/Glycine Pathway Flux

Erin Quan Toyama, Genomics Institute of the Novartis Research Foundation, USA
AMPK Regulation of Mitochondrial Dynamics

14:30—16:30
Workshop 1: Junior Investigator Forum

Macdonald ABC
* Peter A. Crawford, University of Minnesota, USA

William S. Baldwin, Clemson University, USA
Gender Differences in Response to a High-Fat Diet in CYP3A-null Mice

Guenter Haemmerle, University of Graz, Austria
Adipose Tissue Lipolysis Regulates G0S2 and FGF21 Expression in the Liver

Athan Kuliopulos, Oasis Pharmaceuticals, USA
Protease-Activated Receptor-2 (PAR2)–A Novel Therapeutic Target in Nonalcoholic Steatohepatitis (NASH)

Suresh T. Mathews, Auburn University, USA
AICAR Downregulates High Glucose-Induced Expression of Fetuin-A through AMPK-p38MAPK Axis in HepG2 Cells

James Xiaojun Rong, Lilly China Research & Development Center, China
Knockdown of Na+-Coupled Citrate Transporter Slc13a5 in Liver Decreased Body Weight and Improved Insulin Sensitivity in Mice with Pre-Existing Obese, Hyperglycemic Conditions

Takuya F. Sakaguchi, Cleveland Clinic, USA
Gain-of-Function Mutation in cmklr1, a Chemerin Receptor, Leads to Hepatic Steatosis and Inflammation in Zebrafish

Daniel F. Vatner, Yale University School of Medicine, USA
Substrate-Dependent Insulin-Independent Regulation of Hepatic Fatty Acid Esterification

Jim Perfield, Eli Lilly and Company, USA
Insight into the PPAR alpha-Dependent and –Independent Regulation of FGF21

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
The Metabolic Syndrome: Insights from Rare Mitochondrial Diseases

Macdonald DEF
* Sadaf Farooqi, University of Cambridge, UK

Anu Suomalainen Wartiovaara, University of Helsinki, Finland
Mitochondrial Dysfunction Modifies Nutrient Metabolism – Implications to Disease

David Rand, Brown University, USA
Mitonuclear Genetic Interactions in Drosophila Aging and Disease

Douglas C. Wallace, Children's Hospital of Philadelphia, USA
A Mitochondrial Diseases – The Paradigms

Iliana A. Chatzispyrou, Academic Medical Centre, Netherlands
Short Talk: Identification of a Novel Mutation for Perrault Syndrome in the Mitochondrial rRNA Chaperone ERAL1

17:00—19:00
Pathways to NASH, Fibrosis and Hepatocullular Carcinoma

Macdonald ABC
* Brent A. Tetri, St. Louis University, USA

Anna Mae Diehl, Duke University, USA
Hedgehog Signaling and Hepatic Fibrosis

Gyongyi Szabo, University of Massachusetts Medical School, USA
Metabolic Danger Signals in Immune Cell and Hepatocyte Crosstalk in NASH

Roger J. Davis, HHMI/University of Massachusetts Medical School, USA
Metabolic Stress Signaling Mediated by JNK

Maria E. Moreno-Fernandez, Cincinnati Children's Hospital, USA
Short Talk: Role of the IL-17 Axis in the Progression of Non-Alcoholic Fatty Liver Disease

19:00
On Own for Dinner


WEDNESDAY, MARCH 25

07:00—08:00
Breakfast

Frontenac ABC
08:00—11:00
Genetics of the Metabolic Syndrome

Macdonald DEF
* David Rand, Brown University, USA

Norbert Perrimon, Harvard Medical School, USA
Discovery of in vivo Regulators of Glucagon-Induced Hyperglycemia

Jose Antonio Enríquez, Centro Nacional de Investigaciones, Spain
Talk Title to be Announced

Chris Day, Newcastle University, UK
Genetic of NAFLD

Sadaf Farooqi, University of Cambridge, UK
Genetic Basis of Severe Obesity

08:00—11:00
Extra-Hepatic Regulation of Liver Metabolism

Macdonald ABC
* Rosalind A. Coleman, University of North Carolina at Chapel Hill, USA

Jens C. Brüning, Max Planck Institute for Metabolism Research, Germany
Role of Distinct Ceramide Species in Obesity-Associated Insulin Resistance

Frank J. Gonzalez, National Institutes of Health, USA
The Gut Microbiota Influences NAFLD thorough Intestinal FXR Signaling

George N. Ioannou, University of Washington, USA
Role of Cholesterol in the Progression of Steatosis to NASH

Steven A. Kliewer, University of Texas Southwestern Medical Center, USA
Metabolic FGFs 15/19 and 21: From Physiology to Pharmacology

Mattias Bergentall, Gothenburg University, Sweden
Short Talk: The Gut Microbiota Modulates Sucrose-Induced NAFLD

09:20—09:40
Coffee Break

Macdonald Foyer
11:00—13:00
Poster Setup

Frontenac ABC
13:00—22:00
Poster Viewing

Frontenac ABC
11:00—14:30
On Own for Lunch

14:30—16:30
Workshop 2: Disease Mechanism and Therapy

Macdonald DEF
* Junichiro Sonoda, Regeneron Pharmaceuticals, Inc., USA

Laurent Mouchiroud, École Polytechnique Federale de Lausanne – EPFL, Switzerland
Urolithin A Improves Fitness and Lifespan through Mitophagy

Kevin G. Becker, NIA, National Institutes of Health, USA
The Effects of Tomatidine on Three Cell Models of Differentiation

Elizabeth K. Speliotes, University of Michigan, USA
Human Genetic Variants In or Near Mitochondrial Genes Uncouple Obesity from Metabolic Disease

Andrea Galmozzi, The Scripps Research Institute, USA
ThermoMouse: An in vivo Model to Identify Modulators of UCP1 Expression in Brown Adipose Tissue

Ambar Grijalva, Columbia University, USA
Lipid Accumulation in Adipose Tissue Macrophages Reveals a Non-Classical Regulated Pathway of Lipid Release in Adipocytes

Stefan G. Kauschke, Boehringer Ingelheim Pharma, Germany
Evaluation of BACE2 Inhibitors to Delay Progression of beta-Cell Failure in T2DM

Yael Kuperman, Weizmann Institute, Israel
CRFR1 Inhibits AgRP Neurons to Allow Appropriate Sympathetic Nervous System Activity following Challenge

14:30—16:30
Workshop 2: NAFLD Therapeutics

Macdonald ABC
* Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA

Michael L. Chouinard, Eli Lilly and Company, USA
Established Therapies for Diabetes and Dyslipidemia Aimed at CYP7A1 Induction Are Vulnerable to FXR Modulation by Nutrient Fat, Perhaps Limiting their Use in Non-alcoholic Steatohepatitis (NASH)

Derek M. Erion, Takeda, USA
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM Mouse Model of NASH

Tadasuke Komori, Wakayama Medical University, Japan
The Roles of Oncostatin M in the Treatment of Nonalcoholic Fatty Liver Disease in Mice

Xiaoxin Wang, University of Colorado Denver, USA
Treatment with the FXR-TGR5 Dual Agonist INT-767 Decreases NAFLD-NASH in Mice Fed a Western Diet

Eyal Breitbart, VBL Therapeutics, Israel
TLR4 Complex Antagonist Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis

Narayanan Hariharan, Tekmira Pharmaceuticals, Canada
Novel RNAi-Lipid Nanoparticle Therapeutics for Hypertriglyceridemia

Moshe Levi, Georgetown University, USA
Bile Acid Sequestrant Prevents NAFLD/NASH in Diet-Induced Obesity and Insulin Resistant Mice

Mukul R. Jain, Zydus Research Centre, India
Efficacy of Saroglitazar, a Novel PPAR alpha/gamma Agonist in a Mouse Model of Non-Alcoholic Steatohepatitis

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—19:00
Therapy of the Metabolic Syndrome

Macdonald DEF
* Ajay Chawla, Merck and University of California, San Francisco, USA

Matthias H. Tschöp, Helmholtz Zentrum München and Technische Universität München, Germany
Novel Poly-Pharmacy for the Treatment of Obesity and Diabetes

Patrick R. Griffin, The Scripps Research Institute, USA
Pharmacological Repression of PPARG Improves Metabolic Parameters and Promotes Osteogenesis

Saswata Talukdar, Merck Sharp & Dohme, USA
Chronic Administration of a Long-Acting FGF21 Molecule PF-05231023 Decreases Body Weight and Improves Metabolic Profile in Non-Human Primates and Subjects with Type 2 Diabetes

Riekelt H. Houtkooper, Academic Medical Center, Netherlands
Short Talk: Tetracycline-Dependent Mitochondrial Dysfunction Confounds Research and Poses an Environmental Hazard

17:00—19:00
Regulatory Nodes of Hepatic Energy Metabolism

Macdonald ABC
* Douglas G. Mashek, University of Minnesota, USA

Reuben J. Shaw, The Salk Institute for Biological Studies, USA
AMPK: Central Integrator of Metabolic Adaptation and Mitochondrial Homeostasis

Anders M. Näär, University of California, Berkeley, USA

Peter A. Crawford, University of Minnesota, USA
Ketone Metabolism and Hepatic Energy Homeostasis in the Absorptive State

Geula Hanin, Hebrew University, Israel
Short Talk: MicroRNA-132 Is a Reversible Amplifier of Hepatic Lipid Accumulation

19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac ABC
19:30—22:00
Poster Session 3

Frontenac ABC

THURSDAY, MARCH 26

07:00—08:00
Breakfast

Frontenac ABC
08:00—11:00
Metabolic Inflammation, Mitochondria and Metabolic Disease

Macdonald DEF
* Juleen R. Zierath, Karolinska Institutet, Sweden

Ajay Chawla, Merck and University of California, San Francisco, USA
Innate Control of Metabolism

Takashi Kadowaki, University of Tokyo, Japan
Adiponectin Receptor and Metabolic Syndrome: Pathophysiology and Therapeutic Strategy

Anthony W. Ferrante, Columbia University, USA
Immune Regulation of Systemic Metabolism

Keir J. Menzies, University of Ottawa, Canada
Short Talk: NAD+ Repletion Improves the Mdx Mouse Muscle Phenotype by Countering Increased Levels of PARylation

Rudolf J. Wiesner, University of Cologne, Germany
Short Talk: Inhibition of Mitochondrial Complex I by Metformin Induces a Futile Lactate Cycle, which Increases Energy Expenditure and Slows Down Development of Type 2 Diabetes (T2DM)

08:00—11:00
TAG Synthesis and Turnover

Macdonald ABC
* Brian N. Finck, Washington University School of Medicine, USA

Rosalind A. Coleman, University of North Carolina at Chapel Hill, USA
Hepatic Lipid Synthesis and Insulin Resistance

Douglas G. Mashek, University of Minnesota, USA
TAG Hydrolysis as a Branch Point in Hepatic Metabolism

Robert V. Farese Jr., Harvard School of Public Health, USA
Mechanisms and Consequences of Lipid Storage

Elizabeth J. Parks, University of Missouri, USA
In vivo Quantitation of Intracellular TAG Assembly in Humans

Ryan J. Schulze, Mayo Clinic, USA
Short Talk: Small GTPases as Regulators of Hepatocellular Lipophagy

09:20—09:40
Coffee Break

Macdonald Foyer
11:00—17:00
On Own for Lunch

16:30—17:00
Coffee Available

Macdonald Foyer
17:00—18:45
Metabolic Syndrome and Muscle Energy Homeostasis

Macdonald DEF
* David D. Moore, Baylor College of Medicine, USA

Julie St-Pierre, McGill University, Canada
Modulation of Mitochondrial Metabolism and Cellular Bioenergetics

Juleen R. Zierath, Karolinska Institutet, Sweden
Altered DNA Methylation of Glycolytic and Lipogenic Genes in Skeletal Muscle and Liver from Obese and Type 2 Diabetic Patients

Satchidananda Panda, The Salk Institute for Biological Studies, USA
Eating Pattern and Metabolic Diseases

17:00—18:45
Hepatic Metabolic Alterations Associated with NAFLD

Macdonald ABC
* Jay D. Horton, University of Texas Southwestern Medical Center, USA

Jay D. Horton, University of Texas Southwestern Medical Center, USA
Molecular Mediators of Nonalcoholic Fatty Liver Disease

Mark A. Herman, Duke University Medical Center, USA
ChREBP Isoforms Link Glucose and Lipid Metabolism

Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Role of Autophagy in Hepatic Lipid Homeostasis

18:45—19:00
Meeting Wrap Up: Outcomes and Future Directions (Organizers)

Macdonald ABCDEF
18:45—19:00
Meeting Wrap Up: Outcomes and Future Directions (Organizers)

Macdonald ABCDEF
19:00—20:00
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Frontenac ABC
20:00—23:00
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Frontenac ABC

FRIDAY, MARCH 27

 
Departure


*Session Chair †Invited, not yet responded.


We gratefully acknowledge support for this conference from:


Directors' Fund

These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.

Keystone Symposia thanks our Sponsors(s) for generously supporting this meeting:

Nestlé Institute of Health Sciences Novo Nordisk A/S

We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 5R13DK104611-01



We gratefully acknowledge additional support for this conference from:

Adipogen International ALPCO Diagnostics
Cell Signaling Technology, Inc. Seahorse Bioscience, Inc.

We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations

If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Corporate Relations, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179